• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
    • Cardiovascular
    • Orthopedics
  • Wall Street Beat
    • Funding Roundup
    • Mergers & Acquisitions
  • Podcasts & Webinars
    • Podcasts
    • Webinars
  • Resources
    • About MassDevice
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech 100 Index
    • Videos
    • Whitepapers
  • DeviceTalks Tuesdays
  • Coronavirus: Live updates

Novo Nordisk

10 leading pharma executives you need to know

April 25, 2022 By Brian Buntz

Given the complexity of the pharmaceutical business, it can be challenging to gauge the performance of any chief executive in the space. That said, CEOs’ annualized return over tenure as CEO over their term can hint at performance. In addition, rating sites like Glassdoor also indicate CEOs’ popularity. Here, we parsed a range of metrics, […]

Filed Under: Blog, Business/Financial News, Featured, News Well, Pharmaceutical Tagged With: AbbVie, Argenx, Eli Lilly, Evotec, Genmab, leadership, Novo Nordisk, Pfizer, Pharma 50, pharma execs, Sartorius Stedim Biotech, Thermo Fisher Scientific, West Pharmaceutical Services

Novo Nordisk completes acquisition of Dicerna Pharmaceuticals

December 28, 2021 By Sean Whooley

Novo Nordisk (NYSE:NVO) announced today that its acquisition of Dicerna Pharmaceuticals (NSDQ:DRNA) has been completed. Completion of the acquisition, initially announced on Nov. 18, 2021, follows the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 (HSR) in connected on with Novo Nordisk’s cash tender offer for Dicerna at 11:59 p.m. […]

Filed Under: Business/Financial News, Diabetes, Drug Pumps, Drug-Device Combinations, Featured, Mergers & Acquisitions, Wall Street Beat Tagged With: Dicerna Pharmaceuticals, Novo Nordisk

Waiting period for Novo Nordisk’s proposed acquisition of Dicerna expires

December 27, 2021 By Sean Whooley

Dicerna Pharmaceuticals (NSDQ:DRNA) announced that a waiting period for a proposed acquisition by Novo Nordisk (NYSE:NVO) has expired. The announcement, made on Dec. 25, confirmed that the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 (HSR) in connected on with Novo Nordisk’s cash tender offer for Dicerna expired at 11:59 p.m. ET on Dec. 24, 2021. […]

Filed Under: Business/Financial News, Diabetes, Drug Pumps, Drug-Device Combinations, Mergers & Acquisitions, News Well, Pharmaceutical, Wall Street Beat Tagged With: Dicerna Pharmaceuticals, Novo Nordisk

Novo Nordisk Foundation, Harvard, MIT launch research center with focus on diabetes

September 15, 2021 By Sean Whooley

The Novo Nordisk Foundation, the Broad Institute of MIT and Harvard have launched an initiative to gain insights into disease mechanisms. To accelerate efforts to mine genetic data for insights into mechanisms — and eventually rationally design treatments — the trio of entities launched the Novo Nordisk Foundation Center for Genomic Mechanisms of Disease based […]

Filed Under: Business/Financial News, Diabetes, Featured, Funding Roundup, Research & Development Tagged With: Broad Institute, Harvard, mit, Novo Nordisk

Walmart teams up with Novo Nordisk to launch private-brand analog insulin 

June 30, 2021 By Brian Buntz

Walmart (NYSE:WMT) is launching what it describes as the first private label analog insulin. The company estimates the insulin products will save customers between 58% and 70% of the cost of branded insulin. Novo Nordisk (NYSE:NVO) will manufacture the analog insulin, which is a type of lab-grown insulin genetically engineered to optimize glucose control. The […]

Filed Under: Blog, Diabetes, Featured Tagged With: analog insulin, diabetes, FlexPen, insulin, Novo Nordisk, Walmart

Bigfoot Biomedical wins FDA clearance for smart insulin pen cap system

May 10, 2021 By Sean Whooley

Bigfoot Biomedical announced today that it received FDA 510(k) clearance for its Bigfoot Unity diabetes management system. Milpitas, Calif.-based Bigfoot’s first-of-its-kind Bigfoot Unity system features connected smart pen caps designed to recommend insulin doses for diabetes patients using multiple daily injection (MDI) therapy, according to a news release. Get the full story at our sister site, […]

Filed Under: 510(k), Diabetes, Drug-Device Combinations, Featured, Food & Drug Administration (FDA), Regulatory/Compliance Tagged With: Abbott, Bigfoot Biomedical, Eli Lilly & Co., FDA, Novo Nordisk, Sanofi

Once-a-week insulin dosing shows promise in studies

April 19, 2021 By Sean Whooley

Studies suggest that a new once-per-week injectable insulin therapy is safe and as effective as daily injections for those with type 2 diabetes. Two international clinical trials published today in Diabetes Care found that the once-weekly treatment has the potential to offer a convenient alternative to daily insulin shots for those with type 2 diabetes, according […]

Filed Under: Clinical Trials, Diabetes, Drug-Device Combinations, Featured Tagged With: diabetes, Novo Nordisk

The top 5 pharma firms by reputation

April 12, 2021 By Brian Buntz

Recent research from reputation data specialist RepTrak (Boston) indicates that the pharma industry had the largest year-over-year reputational improvement of any sector, according to its roundup of top 100 corporations. The sector saw significant gains in consumers’ perception of its citizenship and governance.  Now ranked eighth overall, the pharma industry came in just ahead of […]

Filed Under: Pharmaceutical Tagged With: Bristol-Myers Squibb Co., Eli Lilly & Co., Novo Nordisk, pharma industry, RepTrak, reputation, Roche, Sanofi

7 medtech advances to improve diabetes treatment

January 10, 2020 By Sean Whooley

Medtech and pharmaceutical companies have made several important strides over the past year when it comes to improving diabetes treatment. Multiple treatments and technologies have cleared regulatory hurdles and are now hitting the market and making the process of living with diabetes that much more manageable. Several different styles of therapy and devices have come […]

Pages: Page 1 Page 2 Page 3 Page 4 Page 5 Page 6 Page 7 Page 8

Filed Under: Diabetes, Drug-Device Combinations, Featured, Food & Drug Administration (FDA), Pharmaceutical, Regulatory/Compliance, Software / IT Tagged With: DarioHealth Corp, FDA, Medtronic, Novo Nordisk, One Drop, OptiScan, popsdiabetescare, Senseonics, tandemdiabetes, Valeritas

Insulet wins FDA nod for Omnipod with Novo Nordisk’s Fiasp insulin

October 28, 2019 By Sean Whooley

Insulet (NSDQ:PODD) said last week that it won FDA clearance for the use of Novo Nordisk‘s (NYSE:NVO) Fiasp insulin with the Omnipod insulin management platform. Acton, Mass.-based Insulet said it completed extensive testing to ensure that Fiasp is safe and usable with the Omnipod and Omnipod Dash systems. It’s the first insulin pump in the U.S. […]

Filed Under: Diabetes, Drug-Device Combinations, Food & Drug Administration (FDA) Tagged With: FDA, Insulet, Novo Nordisk

FDA OKs Novo Nordisk’s Fiasp for infusion pumps

October 22, 2019 By Sean Whooley

Novo Nordisk (NYSE:NVO) said today that it won an expanded label from the FDA for its Fiasp fast-acting insulin aspart injection for use with infusion pumps by adults with Type 1 or Type 2 diabetes. Fiasp won FDA approval in 2017 for use in intravenous infusion under professional supervision or by subcutaneous multiple daily injection in […]

Filed Under: Diabetes, Drug-Device Combinations, Food & Drug Administration (FDA) Tagged With: FDA, Novo Nordisk

  • Go to page 1
  • Go to page 2
  • Go to page 3
  • Interim pages omitted …
  • Go to page 8
  • Go to Next Page »

Primary Sidebar

DeviceTalks Weekly

July 1, 2022
Boston Scientific CEO Mike Mahoney on building a corporate culture that drives high growth results
See More >

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Medtech news in a minute?
We Deliver!

MassDevice Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World

Device Talks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our Device Talks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us
Add us on Facebook Follow us on Twitter Connect with us on LinkedIn Follow us on YouTube

Copyright © 2022 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS